Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally

Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally Ann Surg Oncol (2018) 25:1860–1867 https://doi.org/10.1245/s10434-018-6487-5 OR IG INA L A R TIC L E – PA NC REATIC TU MO RS Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally Waseem Lutfi, BS, Mazen S. Zenati, MD, MPH, PhD, Amer H. Zureikat, MD, Herbert J. Zeh, MD, and Melissa E. Hogg, MD, MS Scaife Hall, Pittsburgh ABSTRACT negative predictors of ET despite higher ET adherence Background and Purpose. National adherence to treat- overall (P \ 0.01). ment guidelines for pancreatic ductal adenocarcinoma Conclusions. Patient and hospital factors impact ET of (PDAC) is a concern. This study aims to evaluate national PDAC on a national level. These treatment disparities for expected treatment (ET) adherence for all PDAC stages. PDAC are concerning, even at high-volume academic We hypothesized that both patient and hospital demo- centers. Future studies need to identify the causes of graphics are associated with national ET disparities for treatment disparities for PDAC with intervention measures PDAC. aimed to relieve treatment disparities. Methods. Clinical stage I through IV PDAC patients were evaluated using the National Cancer Data Base from 2004 to 2013. ET was defined as surgery for stage I/II, National adherence to treatment guidelines for chemotherapy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally

Loading next page...
 
/lp/springer_journal/health-disparities-impact-expected-treatment-of-pancreatic-ductal-E6YNqYQkWX
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
D.O.I.
10.1245/s10434-018-6487-5
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2018) 25:1860–1867 https://doi.org/10.1245/s10434-018-6487-5 OR IG INA L A R TIC L E – PA NC REATIC TU MO RS Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally Waseem Lutfi, BS, Mazen S. Zenati, MD, MPH, PhD, Amer H. Zureikat, MD, Herbert J. Zeh, MD, and Melissa E. Hogg, MD, MS Scaife Hall, Pittsburgh ABSTRACT negative predictors of ET despite higher ET adherence Background and Purpose. National adherence to treat- overall (P \ 0.01). ment guidelines for pancreatic ductal adenocarcinoma Conclusions. Patient and hospital factors impact ET of (PDAC) is a concern. This study aims to evaluate national PDAC on a national level. These treatment disparities for expected treatment (ET) adherence for all PDAC stages. PDAC are concerning, even at high-volume academic We hypothesized that both patient and hospital demo- centers. Future studies need to identify the causes of graphics are associated with national ET disparities for treatment disparities for PDAC with intervention measures PDAC. aimed to relieve treatment disparities. Methods. Clinical stage I through IV PDAC patients were evaluated using the National Cancer Data Base from 2004 to 2013. ET was defined as surgery for stage I/II, National adherence to treatment guidelines for chemotherapy

Journal

Annals of Surgical OncologySpringer Journals

Published: Apr 24, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off